期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
瑞舒伐他汀对高血压患者内皮功能及hs-CRP的影响 被引量:2
1
作者 吴淼 陈漠水 +2 位作者 邢波 杜子军 林德洪 《实用临床医药杂志》 CAS 2012年第15期88-90,共3页
目的研究瑞舒伐他汀对单纯血压患者内皮功能及hs-CRP的影响。方法 67例单纯性高血压患者随机分为对照组(34例)和实验组(33例),分别给予瑞舒伐他汀(10 mg QN)或安慰剂治疗3月,观察血浆超敏C反应蛋白(hs-CRP)、LDL-C、内皮依赖的舒张功能(... 目的研究瑞舒伐他汀对单纯血压患者内皮功能及hs-CRP的影响。方法 67例单纯性高血压患者随机分为对照组(34例)和实验组(33例),分别给予瑞舒伐他汀(10 mg QN)或安慰剂治疗3月,观察血浆超敏C反应蛋白(hs-CRP)、LDL-C、内皮依赖的舒张功能(FMD)和非内皮依赖的舒张功能(NMD)的变化。结果治疗3月后,与治疗前比较,实验组的hs-CRP[(6.98±1.20)mg/L vs(6.56±1.08)mg/L,P<0.05]降低,FMD[(6.74±0.64)%vs(7.81±1.37)%,P<0.05]和NMD[(16.59±0.54)%vs(18.19±0.86)%,P<0.05]升高,均具有统计学差异,LDL-C无显著改变(P>0.05)。对照组中hs-CRP、LDL-C、FMD、NMD治疗前后比较均无统计学差异(P>0.05)。结论瑞舒伐他汀可改善单纯高血压患者的内皮功能,降低hs-CRP的水平。 展开更多
关键词 瑞舒伐他汀 高血压 超敏C反应蛋白 内皮依赖的舒张功能(FMD) 非内皮依赖的舒张功能(nmd)
下载PDF
Association between Homa Index and Vascular Endothelial Dysfunction in Type 2 Diabetic Patients
2
作者 N. Rama Kumari I. Bhaskara Raju +1 位作者 M. Aruna Devi M. Pallam Praveen 《Open Journal of Internal Medicine》 2014年第4期123-129,共7页
Introduction: In recent years, flow mediated dilatation (FMD) has become a popular technique in cardiovascular medicine. HOMA-IR was accepted to determine the insulin sensitivity as a valuable standard. In this study,... Introduction: In recent years, flow mediated dilatation (FMD) has become a popular technique in cardiovascular medicine. HOMA-IR was accepted to determine the insulin sensitivity as a valuable standard. In this study, we evaluated the association between HOMA-IR (homeostasis model assessment of insulin resistance) and vascular endothelial dysfunction, as assessed by endothelium- dependent flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD), in type 2 Diabetic (DM) patients. Material and Methods: Eighty four (84) consecutive out-patients were enrolled. HOMA-IR was calculated as fasting insulin (μU/ml) multiplied by fasting plasma glucose (FPG) (mg/dl) and divided by 405. The ultrasound method for measuring FMD and NMD has been used. Out of 84 patients, 42 patients were in control group and 42 patients were in diabetic group, which were further subdivided into two groups based on HOMA-IR > 3.0 and above was considered as Group I and HOMA IR < 3.0 and below was considered as Group II. Fasting Plasma Glucose (mmol/dl) (7.74 ± 2.56, 6.81 ± 1.9, p < 0.001) and Fasting Insulin (μU/dl) (13.26 ± 8.09, 6.65 ± 2.36, p < 0.001) were statistically significant in Group I. The baseline mean FMD in controls and cases (Group I and Group II) was 15.36 ± 9.56, 4.15 ± 2.29, 12.21 ± 6.24 (p < 0.001) respectively. By logistic regression analysis the factors which were effective on FMD percentage change (<5.5%) in Group I were BMI (p < 0.02), plasma Insulin (p < 0.04) and triglycerides (p < 0.02). There was a negative co-relation for FMD, NMD and HOMA-IR. Discussion: We conclude that increased HOMA-IR in hyperglycaemic patients is associated with severe endothelial dysfunction which is the marker of the atherosclerosis. Thus the measurement of endothelial vasomotor function which is a comprehensive analysis of atherosclerotic burden may provide a better predictive value of future cardiovascular events than the analysis of each of the traditional risk factors alone. 展开更多
关键词 Flow MEDIATED dilatation (FMD) Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) nitroglycerin-mediated dilatation (nmd)
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部